fluoxetine has been researched along with Epilepsy in 37 studies
Fluoxetine: The first highly specific serotonin uptake inhibitor. It is used as an antidepressant and often has a more acceptable side-effects profile than traditional antidepressants.
fluoxetine : A racemate comprising equimolar amounts of (R)- and (S)-fluoxetine. A selective serotonin reuptake inhibitor (SSRI), it is used (generally as the hydrochloride salt) for the treatment of depression (and the depressive phase of bipolar disorder), bullimia nervosa, and obsessive-compulsive disorder.
N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine : An aromatic ether consisting of 4-trifluoromethylphenol in which the hydrogen of the phenolic hydroxy group is replaced by a 3-(methylamino)-1-phenylpropyl group.
Epilepsy: A disorder characterized by recurrent episodes of paroxysmal brain dysfunction due to a sudden, disorderly, and excessive neuronal discharge. Epilepsy classification systems are generally based upon: (1) clinical features of the seizure episodes (e.g., motor seizure), (2) etiology (e.g., post-traumatic), (3) anatomic site of seizure origin (e.g., frontal lobe seizure), (4) tendency to spread to other structures in the brain, and (5) temporal patterns (e.g., nocturnal epilepsy). (From Adams et al., Principles of Neurology, 6th ed, p313)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Nineteen mentally retarded inpatients with epilepsy and a history of current or recent aggressive behavior were treated with 20 mg of fluoxetine daily." | 9.08 | Effects of fluoxetine on aggressive behavior of adult inpatients with mental retardation and epilepsy. ( Ciani, N; Nuccetelli, F; Pasini, A; Troisi, A; Vicario, E, 1995) |
| "Serotonin and fluoxetine, but not sumatriptan, alleviated PTZ-induced seizures by prolonging onset times of myoclonic-jerk and generalized tonic-clonic seizures." | 8.12 | Endogenous and exogenous serotonin, but not sumatriptan, ameliorate seizures and neuroinflammation in the pentylenetetrazole-induced seizure model in rats. ( Kilinc, E; Kılınc, YB; Torun, IE, 2022) |
| " The main objective of this work was to investigate the effect of the selective 5-HT selective reuptake inhibitor (SSRI) fluoxetine administered subacutely (10mg/kg/day×7 days) on the eventual metabolic impairment induced by the lithium-pilocarpine model of epilepsy in rats." | 7.81 | Subacute administration of fluoxetine prevents short-term brain hypometabolism and reduces brain damage markers induced by the lithium-pilocarpine model of epilepsy in rats. ( Bascuñana, P; de Cristóbal, J; Delgado, M; Fernández de la Rosa, R; García-García, L; Pozo, MA; Shiha, AA, 2015) |
| "Status epilepticus was induced in the rats by administration of pilocarpine 350 mg/kg i." | 7.77 | Piperine protects epilepsy associated depression: a study on role of monoamines. ( Nayak, S; Pal, A; Sahu, PK; Swain, T, 2011) |
| "Fluoxetine (20 mg/kg) and TFMPP (5 mg/kg) were administered to rats with pilocarpine-induced epilepsy." | 7.71 | Effects of fluoxetine and TFMPP on spontaneous seizures in rats with pilocarpine-induced epilepsy. ( Dudek, FE; Hernandez, EJ; Williams, PA, 2002) |
| "This study was designed to demonstrate a role of serotonin in the anticonvulsant effect of fluoxetine, a serotonin reuptake inhibitor, in genetically epilepsy-prone rats." | 7.69 | Role of serotonin in the anticonvulsant effect of fluoxetine in genetically epilepsy-prone rats. ( Cheong, JH; Dailey, JW; Jobe, PC; Ko, KH; Yan, QS, 1994) |
| "To test the hypothesis that fluoxetine may be a useful adjunct to antiepileptic therapy, we treated with fluoxetine (20-40 mg/day) nine patients suffering from medically intractable epilepsy with daily seizures." | 7.69 | Lack of potentiation of anticonvulsant effect by fluoxetine in drug-resistant epilepsy. ( Baldinetti, F; Diomedi, M; Gigli, GL; Girolami, E; Marciani, MG; Pasini, A; Troisi, A, 1994) |
| "Fluoxetine, an antidepressant and inhibitor of serotonin reuptake, was evaluated as an anticonvulsant in genetically epilepsy-prone rats (GEPRs) because seizure predisposition in GEPRs is partially dependent on deficits in brain serotonin." | 7.68 | Effects of fluoxetine on convulsions and on brain serotonin as detected by microdialysis in genetically epilepsy-prone rats. ( Burger, RL; Dailey, JW; Jobe, PC; Mishra, PK; Yan, QS, 1992) |
| "Furthermore, children with highly refractory epilepsy are at particular risk of sudden unexpected death." | 5.62 | Fluoxetine as adjunctive therapy in pediatric patients with refractory epilepsy: A retrospective analysis. ( Desnous, B; Milh, M; Neveu, J; Villeneuve, N, 2021) |
| "In this sample of children and adolescents with epilepsy and depressive disorders, we observed that SSRIs are a good therapeutic option, considering their efficacy in remission of depressive symptoms, their few adverse effects, and their maintenance of satisfactory seizure control." | 5.34 | Sertraline and fluoxetine: safe treatments for children and adolescents with epilepsy and depression. ( Kuczynski, E; Thomé-Souza, MS; Valente, KD, 2007) |
| "Nineteen mentally retarded inpatients with epilepsy and a history of current or recent aggressive behavior were treated with 20 mg of fluoxetine daily." | 5.08 | Effects of fluoxetine on aggressive behavior of adult inpatients with mental retardation and epilepsy. ( Ciani, N; Nuccetelli, F; Pasini, A; Troisi, A; Vicario, E, 1995) |
| "Pregabalin (PGB) is used in drug-resistant epilepsy." | 4.31 | The investigation of antidepressant and anxiolytic effects of pregabalin and its mechanisms of action in rats. ( Aydın, Ş; Çivgin, ME; Dinçer Öner, S; Kılıç Tatlıcı, C; Kılıç, FS; Yazıcı, ZG; Yıldırım, C, 2023) |
| "Serotonin and fluoxetine, but not sumatriptan, alleviated PTZ-induced seizures by prolonging onset times of myoclonic-jerk and generalized tonic-clonic seizures." | 4.12 | Endogenous and exogenous serotonin, but not sumatriptan, ameliorate seizures and neuroinflammation in the pentylenetetrazole-induced seizure model in rats. ( Kilinc, E; Kılınc, YB; Torun, IE, 2022) |
| " The main objective of this work was to investigate the effect of the selective 5-HT selective reuptake inhibitor (SSRI) fluoxetine administered subacutely (10mg/kg/day×7 days) on the eventual metabolic impairment induced by the lithium-pilocarpine model of epilepsy in rats." | 3.81 | Subacute administration of fluoxetine prevents short-term brain hypometabolism and reduces brain damage markers induced by the lithium-pilocarpine model of epilepsy in rats. ( Bascuñana, P; de Cristóbal, J; Delgado, M; Fernández de la Rosa, R; García-García, L; Pozo, MA; Shiha, AA, 2015) |
| "Status epilepticus was induced in the rats by administration of pilocarpine 350 mg/kg i." | 3.77 | Piperine protects epilepsy associated depression: a study on role of monoamines. ( Nayak, S; Pal, A; Sahu, PK; Swain, T, 2011) |
| " In this study the anticonvulsant actions of norfluoxetine and fluoxetine were studied and compared to those of phenytoin and clonazepam in pentylenetetrazol-induced mouse epilepsy models." | 3.73 | Norfluoxetine and fluoxetine have similar anticonvulsant and Ca2+ channel blocking potencies. ( Harasztosi, C; Kecskeméti, V; Nánási, PP; Pál, B; Riba, P; Rusznák, Z; Szûcs, G; Wagner, R, 2005) |
| "Fluoxetine (20 mg/kg) and TFMPP (5 mg/kg) were administered to rats with pilocarpine-induced epilepsy." | 3.71 | Effects of fluoxetine and TFMPP on spontaneous seizures in rats with pilocarpine-induced epilepsy. ( Dudek, FE; Hernandez, EJ; Williams, PA, 2002) |
| "This study was designed to demonstrate a role of serotonin in the anticonvulsant effect of fluoxetine, a serotonin reuptake inhibitor, in genetically epilepsy-prone rats." | 3.69 | Role of serotonin in the anticonvulsant effect of fluoxetine in genetically epilepsy-prone rats. ( Cheong, JH; Dailey, JW; Jobe, PC; Ko, KH; Yan, QS, 1994) |
| "To test the hypothesis that fluoxetine may be a useful adjunct to antiepileptic therapy, we treated with fluoxetine (20-40 mg/day) nine patients suffering from medically intractable epilepsy with daily seizures." | 3.69 | Lack of potentiation of anticonvulsant effect by fluoxetine in drug-resistant epilepsy. ( Baldinetti, F; Diomedi, M; Gigli, GL; Girolami, E; Marciani, MG; Pasini, A; Troisi, A, 1994) |
| "Fluoxetine, an antidepressant and inhibitor of serotonin reuptake, was evaluated as an anticonvulsant in genetically epilepsy-prone rats (GEPRs) because seizure predisposition in GEPRs is partially dependent on deficits in brain serotonin." | 3.68 | Effects of fluoxetine on convulsions and on brain serotonin as detected by microdialysis in genetically epilepsy-prone rats. ( Burger, RL; Dailey, JW; Jobe, PC; Mishra, PK; Yan, QS, 1992) |
| "Furthermore, children with highly refractory epilepsy are at particular risk of sudden unexpected death." | 1.62 | Fluoxetine as adjunctive therapy in pediatric patients with refractory epilepsy: A retrospective analysis. ( Desnous, B; Milh, M; Neveu, J; Villeneuve, N, 2021) |
| "Depression is the most common psychiatric comorbidity of epilepsy." | 1.62 | Chronically altered NMDAR signaling in epilepsy mediates comorbid depression. ( Dehpour, AR; Hemmati, S; Mohammadi, S; Sadeghi, MA; Vafaei, A; Yousefi-Manesh, H; Zare, M, 2021) |
| "In this sample of children and adolescents with epilepsy and depressive disorders, we observed that SSRIs are a good therapeutic option, considering their efficacy in remission of depressive symptoms, their few adverse effects, and their maintenance of satisfactory seizure control." | 1.34 | Sertraline and fluoxetine: safe treatments for children and adolescents with epilepsy and depression. ( Kuczynski, E; Thomé-Souza, MS; Valente, KD, 2007) |
| "When fluoxetine (3 microM) was applied first neither nifedipine nor omega-conotoxin attenuated the remaining component of the HVA current." | 1.31 | Inhibition of voltage-gated calcium channels by fluoxetine in rat hippocampal pyramidal cells. ( Deák, F; Lasztóczi, B; Pacher, P; Petheö, GL; Spät, A, 2000) |
| "With conservative dosing and close monitoring, combinations of SRIs with bupropion in this uncontrolled clinical series appeared to be safe and often more effective than monotherapy." | 1.30 | Combining serotonin reuptake inhibitors and bupropion in partial responders to antidepressant monotherapy. ( Baldessarini, RJ; Bodkin, JA; Gardner, DM; Lasser, RA; Wines, JD, 1997) |
| "Pretreatment with prazosin (1 microgram/side) significantly diminished the anticonvulsant effectiveness of methoxamine and nisoxetine while prazosin, by itself, had no effects on the seizure intensity." | 1.30 | Anticonvulsant effect of enhancement of noradrenergic transmission in the superior colliculus in genetically epilepsy-prone rats (GEPRs): a microinjection study. ( Dailey, JW; Jobe, PC; Steenbergen, JL; Yan, QS, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 16 (43.24) | 18.2507 |
| 2000's | 7 (18.92) | 29.6817 |
| 2010's | 10 (27.03) | 24.3611 |
| 2020's | 4 (10.81) | 2.80 |
| Authors | Studies |
|---|---|
| Vivier, D | 1 |
| Bennis, K | 1 |
| Lesage, F | 1 |
| Ducki, S | 1 |
| Neveu, J | 1 |
| Villeneuve, N | 1 |
| Milh, M | 1 |
| Desnous, B | 1 |
| Torun, IE | 1 |
| Kılınc, YB | 1 |
| Kilinc, E | 1 |
| Aydın, Ş | 1 |
| Kılıç Tatlıcı, C | 1 |
| Çivgin, ME | 1 |
| Yazıcı, ZG | 1 |
| Yıldırım, C | 1 |
| Dinçer Öner, S | 1 |
| Kılıç, FS | 1 |
| Sadeghi, MA | 1 |
| Hemmati, S | 1 |
| Mohammadi, S | 1 |
| Yousefi-Manesh, H | 1 |
| Vafaei, A | 1 |
| Zare, M | 1 |
| Dehpour, AR | 1 |
| Lovick, T | 1 |
| Cardamone, L | 1 |
| Salzberg, MR | 1 |
| Koe, AS | 1 |
| Ozturk, E | 1 |
| O'Brien, TJ | 1 |
| Jones, NC | 1 |
| Puzerey, PA | 1 |
| Decker, MJ | 1 |
| Galán, RF | 1 |
| Shiha, AA | 1 |
| de Cristóbal, J | 1 |
| Delgado, M | 1 |
| Fernández de la Rosa, R | 1 |
| Bascuñana, P | 1 |
| Pozo, MA | 1 |
| García-García, L | 1 |
| Zeng, C | 1 |
| Long, X | 1 |
| Cotten, JF | 1 |
| Forman, SA | 1 |
| Solt, K | 1 |
| Faingold, CL | 1 |
| Feng, HJ | 1 |
| Lance, S | 1 |
| Ternouth, I | 1 |
| Choi, HC | 1 |
| Kim, YI | 1 |
| Song, HK | 1 |
| Kim, JE | 1 |
| Kim, DS | 1 |
| Kang, TC | 1 |
| Pal, A | 1 |
| Nayak, S | 1 |
| Sahu, PK | 1 |
| Swain, T | 1 |
| Pineda, EA | 1 |
| Hensler, JG | 1 |
| Sankar, R | 1 |
| Shin, D | 1 |
| Burke, TF | 1 |
| Mazarati, AM | 1 |
| Hernandez, EJ | 1 |
| Williams, PA | 1 |
| Dudek, FE | 1 |
| Kecskeméti, V | 1 |
| Rusznák, Z | 1 |
| Riba, P | 1 |
| Pál, B | 1 |
| Wagner, R | 1 |
| Harasztosi, C | 1 |
| Nánási, PP | 1 |
| Szûcs, G | 1 |
| Albano, C | 3 |
| Cupello, A | 1 |
| Mainardi, P | 3 |
| Scarrone, S | 1 |
| Favale, E | 2 |
| Thomé-Souza, MS | 1 |
| Kuczynski, E | 1 |
| Valente, KD | 1 |
| Merrill, MA | 1 |
| Clough, RW | 1 |
| Dailey, JW | 5 |
| Jobe, PC | 5 |
| Browning, RA | 1 |
| Rubino, V | 2 |
| Lunardi, G | 2 |
| Yan, QS | 4 |
| Cheong, JH | 1 |
| Ko, KH | 1 |
| Troisi, A | 3 |
| Vicario, E | 1 |
| Nuccetelli, F | 1 |
| Ciani, N | 1 |
| Pasini, A | 2 |
| Gigli, GL | 1 |
| Diomedi, M | 1 |
| Baldinetti, F | 1 |
| Marciani, MG | 1 |
| Girolami, E | 1 |
| Darley, J | 1 |
| Friedman, EH | 1 |
| Fracassi, M | 1 |
| Pioli, F | 1 |
| Cultrera, S | 1 |
| Bodkin, JA | 1 |
| Lasser, RA | 1 |
| Wines, JD | 1 |
| Gardner, DM | 1 |
| Baldessarini, RJ | 1 |
| Steenbergen, JL | 1 |
| Lu, KT | 1 |
| Gean, PW | 1 |
| Deák, F | 1 |
| Lasztóczi, B | 1 |
| Pacher, P | 1 |
| Petheö, GL | 1 |
| Spät, A | 1 |
| Romerio, SC | 1 |
| Radanowicz, V | 1 |
| Schlienger, RG | 1 |
| Droulers, A | 1 |
| Bodak, N | 1 |
| Oudjhani, M | 1 |
| Lefevre des Noettes, V | 1 |
| Bodak, A | 1 |
| Jalil, P | 1 |
| Mishra, PK | 1 |
| Burger, RL | 1 |
| Thompson, PM | 1 |
| Zebrowski, G | 1 |
| Neuman, RS | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Sequenced Treatment Alternatives to Relieve Adolescent Depression (STAR-AD) a Multicentre Open-label Randomized Controlled Trial Protocol[NCT05814640] | Phase 1/Phase 2 | 520 participants (Anticipated) | Interventional | 2023-02-20 | Recruiting | ||
| Double-Blind, Placebo-Controlled, Randomized Trial of Adjunctive Lisdexamfetamine Dimesylate in Residual Symptoms of Major Depressive Disorder Partially Responsive to Selective Serotonin or Norepinephrine Reuptake Inhibitor Monotherapy[NCT01148979] | Phase 4 | 35 participants (Actual) | Interventional | 2010-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The Montgomery-Asberg Depression Rating Scale Dysphoric Apathy Retardation subfactor (MDAR) is a 5-item subscale of the clinician-administered 10-item Montgomery-Asberg Depression Rating Scale (MADRS). MDAR score can range from 0-30 with a higher score representing a greater severity of depressive symptoms. (NCT01148979)
Timeframe: Baseline to 4 weeks of treatment
| Intervention | scores on a scale (Mean) | ||
|---|---|---|---|
| Baseline Mean MDAR score | Week 4 Mean MDAR score | Change from BL in mean MDAR score | |
| Lisdexamfetamine Dimesylate (Vyvanse) | 13.46 | 6.36 | -7.08 |
| Placebo Adjunct | 12.57 | 9.08 | -3.49 |
1 review available for fluoxetine and Epilepsy
| Article | Year |
|---|---|
Perspectives on the Two-Pore Domain Potassium Channel TREK-1 (TWIK-Related K(+) Channel 1). A Novel Therapeutic Target?
Topics: Arrhythmias, Cardiac; Depression; Epilepsy; Humans; Inflammation; Models, Molecular; Molecular Struc | 2016 |
1 trial available for fluoxetine and Epilepsy
| Article | Year |
|---|---|
Effects of fluoxetine on aggressive behavior of adult inpatients with mental retardation and epilepsy.
Topics: Adult; Aggression; Epilepsy; Female; Fluoxetine; Humans; Individuality; Intellectual Disability; Mal | 1995 |
35 other studies available for fluoxetine and Epilepsy
| Article | Year |
|---|---|
Fluoxetine as adjunctive therapy in pediatric patients with refractory epilepsy: A retrospective analysis.
Topics: Adult; Anticonvulsants; Child; Drug Resistant Epilepsy; Epilepsy; Fluoxetine; Humans; Retrospective | 2021 |
Endogenous and exogenous serotonin, but not sumatriptan, ameliorate seizures and neuroinflammation in the pentylenetetrazole-induced seizure model in rats.
Topics: Animals; Anticonvulsants; Epilepsy; Fluoxetine; Humans; Interleukin-6; Male; Neuroinflammatory Disea | 2022 |
The investigation of antidepressant and anxiolytic effects of pregabalin and its mechanisms of action in rats.
Topics: Amitriptyline; Animals; Anti-Anxiety Agents; Antidepressive Agents; Epilepsy; Fluoxetine; Humans; Ke | 2023 |
Chronically altered NMDAR signaling in epilepsy mediates comorbid depression.
Topics: Animals; Anticonvulsants; Antidepressive Agents; Depression; Epilepsy; Fluoxetine; Indazoles; Male; | 2021 |
SSRIs and the female brain--potential for utilizing steroid-stimulating properties to treat menstrual cycle-linked dysphorias.
Topics: Animals; Brain; Dose-Response Relationship, Drug; Epilepsy; Female; Fluoxetine; GABAergic Neurons; H | 2013 |
Chronic antidepressant treatment accelerates kindling epileptogenesis in rats.
Topics: Amygdala; Analysis of Variance; Animals; Antidepressive Agents; Drug Delivery Systems; Electric Stim | 2014 |
Elevated serotonergic signaling amplifies synaptic noise and facilitates the emergence of epileptiform network oscillations.
Topics: Animals; Computer Simulation; Electrodes, Implanted; Electroencephalography; Epilepsy; Excitatory Po | 2014 |
Subacute administration of fluoxetine prevents short-term brain hypometabolism and reduces brain damage markers induced by the lithium-pilocarpine model of epilepsy in rats.
Topics: Animals; Apoptosis; Astrocytes; Brain; Caspase 3; Disease Models, Animal; Epilepsy; Fluoxetine; Gluc | 2015 |
Fluoxetine prevents respiratory arrest without enhancing ventilation in DBA/1 mice.
Topics: Animals; Death, Sudden; Disease Models, Animal; Epilepsy; Fluoxetine; Mice; Mice, Inbred DBA; Pulmon | 2015 |
Fluoxetine-induced phenytoin toxicity: a clinical reminder about the perils of polypharmacy.
Topics: Antidepressive Agents, Second-Generation; Drug Interactions; Epilepsy; Female; Fluoxetine; Humans; M | 2015 |
Effects of selective serotonin reuptake inhibitors on GABAergic inhibition in the hippocampus of normal and pilocarpine induced epileptic rats.
Topics: Analysis of Variance; Animals; Citalopram; Electroencephalography; Epilepsy; Fluoxetine; gamma-Amino | 2010 |
Piperine protects epilepsy associated depression: a study on role of monoamines.
Topics: Alkaloids; Anhedonia; Animals; Anticonvulsants; Behavior, Animal; Benzodioxoles; Biogenic Monoamines | 2011 |
Interleukin-1β causes fluoxetine resistance in an animal model of epilepsy-associated depression.
Topics: Animals; Antidepressive Agents, Second-Generation; Depression; Disease Models, Animal; Drug Resistan | 2012 |
Effects of fluoxetine and TFMPP on spontaneous seizures in rats with pilocarpine-induced epilepsy.
Topics: Animals; Convulsants; Epilepsy; Fluoxetine; Male; Pilocarpine; Piperazines; Rats; Rats, Sprague-Dawl | 2002 |
Norfluoxetine and fluoxetine have similar anticonvulsant and Ca2+ channel blocking potencies.
Topics: Animals; Anticonvulsants; Barium; Calcium; Calcium Channel Blockers; Calcium Channels; Calcium Signa | 2005 |
Successful treatment of epilepsy with serotonin reuptake inhibitors: proposed mechanism.
Topics: Adolescent; Adult; Aged; Amino Acids; Citalopram; Clinical Trials as Topic; Epilepsy; Female; Fluoxe | 2006 |
Sertraline and fluoxetine: safe treatments for children and adolescents with epilepsy and depression.
Topics: Adolescent; Child; Child, Preschool; Depression; Epilepsy; Female; Fluoxetine; Humans; Male; Neurolo | 2007 |
Localization of the serotonergic terminal fields modulating seizures in the genetically epilepsy-prone rat.
Topics: Animals; Brain; Dihydroxytryptamines; Epilepsy; Epilepsy, Reflex; Female; Fluoxetine; Infusions, Par | 2007 |
Anticonvulsant effect of fluoxetine in humans.
Topics: Adolescent; Adult; Anticonvulsants; Epilepsy; Female; Fluoxetine; Humans; Male; Middle Aged | 1995 |
Role of serotonin in the anticonvulsant effect of fluoxetine in genetically epilepsy-prone rats.
Topics: 5-Hydroxytryptophan; Animals; Anticonvulsants; Epilepsy; Female; Fenclonine; Fluoxetine; Hydroxyindo | 1994 |
Lack of potentiation of anticonvulsant effect by fluoxetine in drug-resistant epilepsy.
Topics: Adolescent; Adult; Anticonvulsants; Depressive Disorder; Dose-Response Relationship, Drug; Drug Ther | 1994 |
Interaction between phenytoin and fluoxetine.
Topics: Adult; Depressive Disorder; Dose-Response Relationship, Drug; Epilepsy; Fluoxetine; Humans; Male; Ph | 1994 |
Evidence that a serotonergic mechanism is involved in the anticonvulsant effect of fluoxetine in genetically epilepsy-prone rats.
Topics: 5-Hydroxytryptophan; Animals; Anticonvulsants; Disease Models, Animal; Drug Synergism; Epilepsy; Fem | 1994 |
Fluoxetine and aggressive behaviour.
Topics: Adult; Aggression; Epilepsy; Fluoxetine; Humans; Intellectual Disability; Selective Serotonin Reupta | 1996 |
Tryptophan and epilepsy.
Topics: Anticonvulsants; Blood-Brain Barrier; Brain; Epilepsy; Fluoxetine; Humans; Selective Serotonin Reupt | 1996 |
Fluoxetine and aggression.
Topics: Aggression; Animals; Behavior, Animal; Epilepsy; Fluoxetine; Humans; Intellectual Disability; Rats | 1997 |
Combining serotonin reuptake inhibitors and bupropion in partial responders to antidepressant monotherapy.
Topics: 1-Naphthylamine; Adult; Aged; Ambulatory Care; Anxiety Disorders; Bupropion; Depressive Disorder; Dr | 1997 |
Anticonvulsant effect of enhancement of noradrenergic transmission in the superior colliculus in genetically epilepsy-prone rats (GEPRs): a microinjection study.
Topics: Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Adrenergic Uptake Inhibitors; Animals; Anti | 1998 |
Endogenous serotonin inhibits epileptiform activity in rat hippocampal CA1 neurons via 5-hydroxytryptamine1A receptor activation.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Barium; Epilepsy; Excitatory Postsynaptic Potential | 1998 |
Inhibition of voltage-gated calcium channels by fluoxetine in rat hippocampal pyramidal cells.
Topics: Action Potentials; Animals; Anticonvulsants; Antidepressive Agents, Second-Generation; Calcium Chann | 2000 |
[SIADH with epileptic seizures and coma in fluoxetine therapy].
Topics: Aged; Aged, 80 and over; Antidepressive Agents, Second-Generation; Coma; Depressive Disorder; Electr | 2000 |
Decrease of valproic acid concentration in the blood when coprescribed with fluoxetine.
Topics: Aged; Aged, 80 and over; Anticonvulsants; Antidepressive Agents, Second-Generation; Depressive Disor | 1997 |
Toxic reaction following the combined administration of fluoxetine and phenytoin: two case reports.
Topics: Aged; Aged, 80 and over; Depressive Disorder; Drug Therapy, Combination; Epilepsy; Female; Fluoxetin | 1992 |
Effects of fluoxetine on convulsions and on brain serotonin as detected by microdialysis in genetically epilepsy-prone rats.
Topics: Animals; Brain; Dialysis; Epilepsy; Female; Fluoxetine; Male; Rats; Seizures; Serotonin; Thalamus | 1992 |
Alteration of neocortical activity in response to noxious stimulation: participation of the dorsal raphe.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Baclofen; Cerebral Cortex; Cortical Synchronization | 1991 |